August 1, 2019 06:54 AM EDTUpdated 10:40 AM

Still trailing far behind a blockbuster rival, Novartis gathers another round of positive survival data for Kisqali

John Carroll

Editor & Founder

Just two months ago, Novartis’ team turned up at ASCO with some clearly positive improved survival rates for a group of pre-menopausal breast cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Still trailing far behind a blockbuster rival, Novartis gathers another round of positive survival data for Kisqali

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Still trail­ing far be­hind a block­buster ri­val, No­var­tis gath­ers an­oth­er round of pos­i­tive sur­vival da­ta for Kisqali

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Still trailing far behind a blockbuster rival, Novartis gathers another round of positive survival data for Kisqali

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.